Cadence Pharmaceuticals Cash from Financing Quarterly:
0.053M for March 31, 2013Cadence Pharmaceuticals Historical Cash from Financing Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 0.053M |
| Dec. 31, 2012 | 0.354M |
| Sept. 30, 2012 | 0.001M |
| June 30, 2012 | 0.007M |
| March 31, 2012 | 0.089M |
| Dec. 31, 2011 | 77.88M |
| Sept. 30, 2011 | -1.558M |
| June 30, 2011 | 0.796M |
| March 31, 2011 | 0.605M |
| Dec. 31, 2010 | 103.67M |
| Sept. 30, 2010 | 0.034M |
| June 30, 2010 | 14.79M |
| March 31, 2010 | -1.469M |
| Dec. 31, 2009 | -1.450M |
About Cash From Financing
An item on a company's cash flow statement. Lists aggregate change in cash position resulting from financing activities. Includes the company's cash inflows and outflows from issuing cash dividends, issuing and selling stock, and adding or changing loans.
Learn More
CADX Cash from Financing Quarterly Benchmarks
| Companies | |
|---|---|
| Bristol-Myers Squibb | -44.00M |
| Dendreon | 2.611M |
| Targacept |
CADX Cash from Financing Quarterly Rankings
| Overall |
78th percentile 1753 of 8002 |
| Sector |
57th percentile 288 of 684 in Healthcare |
| Industry |
48th percentile 127 of 248 in Biotechnology |
CADX Cash from Financing Quarterly Range, Past 5 Years
| Minimum | -2.213M | Jun 2009 |
| Maximum | 103.67M | Dec 2010 |
| Average | 13.45M |